Cargando…
DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial
Autores principales: | Humeau, Laurent, Trimble, Cornelia, Morrow, Matthew, Shen, Xuefei, Dallas, Michael, Weiner, David, Boyer, Jean, Yan, Jian, Kraynyak, Kimberly, Sylvester, Albert, Giffear, Mary, Marcozzi-Pierce, Kathy, Shah, Divya, Broderick, Kate, Khan, Amir, Lee, Jessica, Sardesai, Niranjan, Bargarazzi, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288328/ http://dx.doi.org/10.1186/2051-1426-2-S3-O17 |
Ejemplares similares
-
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
por: Morrow, Matthew P, et al.
Publicado: (2016) -
Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population
por: Hollenberg, Rebecca K., et al.
Publicado: (2019) -
Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL
por: Bhuyan, Prakash K., et al.
Publicado: (2020) -
Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results
por: Aggarwal, Charu, et al.
Publicado: (2015) -
Optimized In Vivo Transfer of Small Interfering RNA Targeting Dermal Tissue Using In Vivo Surface Electroporation
por: Broderick, Kate E, et al.
Publicado: (2012)